×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BCRX – biocryst pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BCRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/15
08:27 pm
bcrx
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? [Yahoo! Finance]
Low
Report
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? [Yahoo! Finance]
12/15
11:02 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
12/12
07:39 am
bcrx
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]
Medium
Report
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]
12/12
07:00 am
bcrx
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
Low
Report
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
12/4
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
04:28 pm
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
12/3
10:37 am
bcrx
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update [Yahoo! Finance]
Medium
Report
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update [Yahoo! Finance]
12/3
07:00 am
bcrx
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
Medium
Report
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
07:00 am
bcrx
biocryst pharmaceuticals, inc.
BEAT
Report
-3.2%
biocryst pharmaceuticals, inc.
8/4/2025
07:00 am
bcrx
biocryst pharmaceuticals, inc.
BEAT
Report
3.9%
biocryst pharmaceuticals, inc.
5/5/2025
07:00 am
bcrx
biocryst pharmaceuticals, inc.
BEAT
Report
16.6%
biocryst pharmaceuticals, inc.
2/24/2025
07:00 am
bcrx
biocryst pharmaceuticals, inc.
MISS
Report
-16.6%
biocryst pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
10/15
07:19 am
Maintains
Market Outperform
Market Outperform
JMP Securities
Medium
Report
4.6%
10/15
07:19 am
Maintains
Market Outperform
Market Outperform
JMP Securities
Medium
Report
4.6%
Date
Time
Symbol
Headline
Impact
12/19
04:22 pm
bcrx
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 18 Filed by: Stonehouse Jon P
Low
Report
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 18 Filed by: Stonehouse Jon P
12/19
04:21 pm
bcrx
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 17 Filed by: Gayer Charles K
Low
Report
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 17 Filed by: Gayer Charles K
12/19
04:17 pm
bcrx
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 17 Filed by: Barnes Alane P
Low
Report
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 17 Filed by: Barnes Alane P
12/19
04:11 pm
bcrx
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 17 Filed by: Ghias Babar
Low
Report
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 17 Filed by: Ghias Babar
12/19
06:05 am
bcrx
Form EFFECT BIOCRYST PHARMACEUTICALS
Low
Report
Form EFFECT BIOCRYST PHARMACEUTICALS
12/18
04:42 pm
bcrx
Form 424B3 BIOCRYST PHARMACEUTICALS
Medium
Report
Form 424B3 BIOCRYST PHARMACEUTICALS
12/16
04:21 pm
bcrx
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 12 Filed by: Gayer Charles K
Medium
Report
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 12 Filed by: Gayer Charles K
12/16
04:13 pm
bcrx
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 12 Filed by: Barnes Alane P
Medium
Report
Form 4 BIOCRYST PHARMACEUTICALS For: Dec 12 Filed by: Barnes Alane P
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/18
Form 4 BIOCRYST PHARMACEUTICALS For: Nov 18 Filed by: Babu Yarlagadda S
19.8%
3/3 Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: LEVIN ALAN G 15.1%
5/29 Form SC 13G BIOCRYST PHARMACEUTICALS Filed by: INTEGRATED CORE STRATEGIES (US) LLC 14.7%
4/9 BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19 13.5%
9/23 BioCryst Appoints Helen Thackray, M.D., to Board of Directors 12.9%
2/25 Form 4 BIOCRYST PHARMACEUTICALS For: Feb 21 Filed by: Jones Michael L 11.9%
3/13 BioCryst Pharmaceuticals: Multiple Value Drivers With A Coronavirus Kicker [Seeking Alpha] 11.9%
1/26 5 Biotech Stocks to Watch With the Coronavirus Scare [The Motley Fool] 11.1%
3/19 BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 11.0%
4/23 BioCryst feels Gilead's remdesivir pain, down 9% [Seeking Alpha] 10.6%
3/3 Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: LEVIN ALAN G 15.1%
5/29 Form SC 13G BIOCRYST PHARMACEUTICALS Filed by: INTEGRATED CORE STRATEGIES (US) LLC 14.7%
4/9 BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19 13.5%
9/23 BioCryst Appoints Helen Thackray, M.D., to Board of Directors 12.9%
2/25 Form 4 BIOCRYST PHARMACEUTICALS For: Feb 21 Filed by: Jones Michael L 11.9%
3/13 BioCryst Pharmaceuticals: Multiple Value Drivers With A Coronavirus Kicker [Seeking Alpha] 11.9%
1/26 5 Biotech Stocks to Watch With the Coronavirus Scare [The Motley Fool] 11.1%
3/19 BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 11.0%
4/23 BioCryst feels Gilead's remdesivir pain, down 9% [Seeking Alpha] 10.6%
TOP News Decliners
5/20
Form 4 BIOCRYST PHARMACEUTICALS For: May 16 Filed by: STAAB THOMAS R II
-52.9%
3/9 BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -34.2%
3/10 Form 8-K BIOCRYST PHARMACEUTICALS For: Mar 04 -23.2%
3/16 BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2 -19.7%
4/9 BioCryst stock rallies on start of coronavirus drug study [MarketWatch] -19.0%
12/11 Form 8-K BIOCRYST PHARMACEUTICALS For: Dec 11 -10.4%
1/12 BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference -10.1%
1/27 Why BioCryst Pharmaceuticals Stock Is Jumping Again Today [The Motley Fool] -10.0%
2/25 BioCryst Appoints Alan G. Levin to Board of Directors -9.4%
5/24 Form 4 BIOCRYST PHARMACEUTICALS For: May 22 Filed by: ASELAGE STEVE -9.2%
3/9 BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -34.2%
3/10 Form 8-K BIOCRYST PHARMACEUTICALS For: Mar 04 -23.2%
3/16 BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2 -19.7%
4/9 BioCryst stock rallies on start of coronavirus drug study [MarketWatch] -19.0%
12/11 Form 8-K BIOCRYST PHARMACEUTICALS For: Dec 11 -10.4%
1/12 BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference -10.1%
1/27 Why BioCryst Pharmaceuticals Stock Is Jumping Again Today [The Motley Fool] -10.0%
2/25 BioCryst Appoints Alan G. Levin to Board of Directors -9.4%
5/24 Form 4 BIOCRYST PHARMACEUTICALS For: May 22 Filed by: ASELAGE STEVE -9.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: